

Brandon A Mahal

List of Publications by Citations

Source: <https://exaly.com/author-pdf/194174/brandon-a-mahal-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152
papers

2,921
citations

28
h-index

48
g-index

162
ext. papers

4,187
ext. citations

6.5
avg, IF

5.36
L-index

#	Paper	IF	Citations
152	Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019 , 5, 975-983	13.4	142
151	Safety of combining radiotherapy with immune-checkpoint inhibition. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 477-494	19.4	132
150	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 778-789	4	127
149	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020 , 5, 659-665	3.3	100
148	Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 704-706	27.4	99
147	Marital status and head and neck cancer outcomes. <i>Cancer</i> , 2015 , 121, 1273-8	6.4	95
146	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1905-12	2.2	92
145	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2015 , 194, 343-9	2.5	88
144	Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. <i>Cancer Cell</i> , 2018 , 34, 549-560.e9	24.3	78
143	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 142-151	4	70
142	Prostate Cancer-Specific Mortality Across Gleason Scores in Black vs Nonblack Men. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 2479-2481	27.4	68
141	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 1660-1667	4	62
140	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1285-91	2.8	62
139	Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. <i>Urology</i> , 2014 , 84, 386-92	1.6	60
138	NGF - the TrkA to successful pain treatment. <i>Journal of Pain Research</i> , 2012 , 5, 279-87	2.9	54
137	Health Insurance Affects Head and Neck Cancer Treatment Patterns and Outcomes. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016 , 74, 1241-7	1.8	53
136	Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv054	9.7	51

135	Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. <i>BJU International</i> , 2015 , 116, 358-65	5.6	51
134	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018 , 74, 146-154	10.2	50
133	Income inequality and treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 18.e7-18.e13	2.8	41
132	Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 683-90	4	41
131	Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, e189-95	3.3	37
130	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016 , 118, 95-101	5.6	36
129	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. <i>Cancer</i> , 2020 , 126, 717-724	6.4	36
128	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv261	9.7	35
127	Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. <i>Cancer</i> , 2016 , 122, 3127-3135	6.4	35
126	Impact of African-American race on presentation, treatment, and survival of head and neck cancer. <i>Oral Oncology</i> , 2014 , 50, 1177-81	4.4	33
125	Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. <i>Cancer</i> , 2016 , 122, 78-83	6.4	29
124	Racial Differences in Genomic Profiling of Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 1083-1085	59.2	28
123	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021 , 79, 374-383	10.2	28
122	Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. <i>Brachytherapy</i> , 2014 , 13, 442-9	2.4	27
121	Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. <i>European Urology</i> , 2019 , 75, 1038-1040	10.2	26
120	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. <i>New England Journal of Medicine</i> , 2019 , 380, 2070-2072	59.2	26
119	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 69-76	5.1	25
118	Asian Americans and prostate cancer: A nationwide population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 233.e7-15	2.8	24

117	Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. <i>Cancer</i> , 2019 , 125, 3164-3171	6.4	23
116	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020 , 6, 735-743	13.4	23
115	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019 , 25, 2450-2457	12.9	23
114	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology, The</i> , 2021 , 22, 402-410	21.7	21
113	Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States. <i>JAMA Oncology</i> , 2019 , 5, 735-737	13.4	20
112	Risk of prostate cancer mortality in men with a history of prior cancer. <i>BJU International</i> , 2016 , 117, E20-8.6	8.6	19
111	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. <i>Cancer</i> , 2016 , 122, 1505-12	6.4	19
110	Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015. <i>JAMA Network Open</i> , 2019 , 2, e193759	10.4	18
109	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021 , 4, 670	6.7	18
108	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. <i>JAMA Network Open</i> , 2020 , 3, e201839	10.4	17
107	Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. <i>Cancer</i> , 2018 , 124, 752-759	6.4	17
106	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016 , 122, 3371-3377	6.4	17
105	Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. <i>Journal of Geriatric Oncology</i> , 2014 , 5, 352-8	3.6	17
104	The role of phenotyping in chronic prostatitis/chronic pelvic pain syndrome. <i>Current Urology Reports</i> , 2011 , 12, 297-303	2.9	17
103	Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. <i>Journal of Urology</i> , 2019 , 202, 973-978	2.5	17
102	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019 , 201, 735-741	2.5	16
101	Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020 , 6, 1630-1632	13.4	16
100	Trends in Smoking and e-Cigarette Use Among US Patients With Cancer, 2014-2017. <i>JAMA Oncology</i> , 2019 , 5, 426-428	13.4	16

99	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. <i>Clinical Cancer Research</i> , 2019 , 25, 4290-4299	12.9	15
98	Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e1-6	3.3	15
97	Racial Disparities in Patient-Reported Measures of Physician Cultural Competency Among Cancer Survivors in the United States. <i>JAMA Oncology</i> , 2020 , 6, 152-154	13.4	15
96	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020 , 6, 1912-1920	13.4	15
95	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 57.e15-22	2.8	14
94	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with 50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. <i>Urology</i> , 2016 , 87, 125-32	1.6	14
93	Who bears the greatest burden of aggressive treatment of indolent prostate cancer?. <i>American Journal of Medicine</i> , 2015 , 128, 609-16	2.4	14
92	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1049-1058	7.3	14
91	Travel distance and stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2018 , 124, 1141-1149	11.4	14
90	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 525-30.e1-3	3.3	13
89	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. <i>European Urology Focus</i> , 2016 , 2, 532-539	5.1	13
88	Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2019 , 154, 595-601	4.9	13
87	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 330.e19-25	2.8	12
86	Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. <i>Radiation Oncology</i> , 2015 , 10, 155	4.2	12
85	A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2019 , 18, 186-191	2.4	12
84	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019 , 75, 35-41	10.2	12
83	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 226-234	3.3	12
82	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3024-3031	2.2	11

81	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020 , 151, 26-32	5.3	11
80	National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e167-72	3.3	10
79	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016 , 15, 695-700	2.4	10
78	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , 2019 , 125, 3338-3346	6.4	10
77	Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. <i>Cancer</i> , 2017 , 123, 4832-4840	6.4	10
76	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 163-167 ^{2.7}	2.7	10
75	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020 , 5, 26-32	3.3	10
74	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020 , 78, 327-332	10.2	9
73	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 953-959	2.7	9
72	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 421-8	7.3	9
71	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. <i>BJU International</i> , 2016 , 118, 279-85	5.6	9
70	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 338-343	4	8
69	Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017. <i>JAMA Oncology</i> , 2019 , 5, e191973	13.4	8
68	Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 413-414	13.4	8
67	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , 2018 , 131, 517-523	2.4	8
66	Outcomes of HPV-Associated Squamous Cell Carcinoma of the Head and Neck: Impact of Race and Socioeconomic Status. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 177-184 ^{7.3}	7.3	8
65	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. <i>European Urology Oncology</i> , 2019 , 2, 405-412	6.7	8
64	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 563-569.e3	3.3	7

63	Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 53-58	4	7
62	Hydrogel Spacing for Radiotherapy of Prostate Cancer: A Review of the Literature. <i>Urology Practice</i> , 2014 , 1, 79-85	0.8	7
61	General and Health-Related Internet Use Among Cancer Survivors in the United States: A 2013-2018 Cross-Sectional Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1468-1475	7.3	7
60	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. <i>Clinical Cancer Research</i> , 2021 , 27, 2416-2423	12.9	7
59	Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC. <i>Oral Oncology</i> , 2019 , 98, 28-34	4.4	6
58	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 646-653	6.2	6
57	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 1279-1285	4	6
56	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019 , 125, 1319-1329	6.4	6
55	Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. <i>Radiotherapy and Oncology</i> , 2021 , 154, 207-213	5.3	6
54	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 542.e25-542.e32	2.8	5
53	Financial worry and psychological distress among cancer survivors in the United States, 2013-2018. <i>Supportive Care in Cancer</i> , 2021 , 29, 5523-5535	3.9	5
52	Examining the Racial Disparities in Prostate Cancer. <i>Urology</i> , 2021 ,	1.6	5
51	Validation of a subclassification for high-risk prostate cancer in a prospective cohort. <i>Cancer</i> , 2020 , 126, 2132-2138	6.4	4
50	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 621-627	4	4
49	Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2015 , 14, 511-6	2.4	4
48	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. <i>Cancer</i> , 2020 , 126, 1407-1412	6.4	4
47	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021 , 79, 717-721	10.2	4
46	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 179-183	6.2	4

45	Psychological distress and cognition among long-term survivors of adolescent and young adult cancer in the USA. <i>Journal of Cancer Survivorship</i> , 2021 , 15, 776-784	5.1	4
44	Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. <i>European Urology</i> , 2020 , 78, 637-639	10.2	3
43	Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities. <i>Prostate</i> , 2020 , 80, 1128-1133	4.2	3
42	Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. <i>Cancer</i> , 2021 , 127, 2714-2723	6.4	3
41	Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States. <i>Cancer</i> , 2021 , 127, 249-256	6.4	3
40	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. <i>Clinical Cancer Research</i> , 2021 , 27, 2807-2815	12.9	3
39	Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma. <i>JCO Oncology Practice</i> , 2021 , 17, e1489-e1501	2.3	3
38	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. <i>European Urology Oncology</i> , 2021 ,	6.7	3
37	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 246-254.e5	3.3	2
36	Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. <i>Cancer</i> , 2021 , 127, 2213-2221	6.4	2
35	HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. <i>Oral Oncology</i> , 2018 , 86, 69-74	4.4	2
34	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.. <i>JAMA Network Open</i> , 2021 , 4, e2139769	10.4	2
33	Sex Disparity and Copy Number Alterations in Esophageal Squamous Cell Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1207-1209	6.9	1
32	Racial Disparities in Low-Risk Prostate Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1727-1728	27.4	1
31	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 936-940	4	1
30	Mandated health insurance increases rates of elective knee surgery. <i>World Journal of Orthopedics</i> , 2019 , 10, 81-89	2.2	1
29	Reporting of Racial Health Disparities Research: Are We Making Progress?. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101780	2.2	1
28	Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. <i>JCO Oncology Practice</i> , 2021 , OP2100412	2.3	1

27	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 735.e9-735.e15	2.8	1
26	Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021 , 41, 1-12	7.1	1
25	The Use of e-Cigarettes in Patients With Cancer-A Double Shipwreck-In Reply. <i>JAMA Oncology</i> , 2019 , 5, 1372	13.4	1
24	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 130.e17-130.e24	2.8	1
23	Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 727-734	7.3	1
22	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021 , 154, 208-214	2.6	1
21	Looking beyond the Western lens: How culture and identity influence perceptions of empathy in patient-clinician relationships.. <i>Cancer</i> , 2021 ,	6.4	1
20	Psychological Distress and Access to Mental Health Services Among Cancer Survivors: a National Health Interview Survey Analysis. <i>Journal of General Internal Medicine</i> , 2021 , 36, 3243-3245	4	0
19	Mental Distress and Mental Health Services Receipt in Foreign-Born Survivors of Cancer: a National Health Interview Survey Analysis. <i>Journal of General Internal Medicine</i> , 2021 , 36, 2495-2498	4	0
18	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 733-741	2.1	0
17	Surface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: A single-center case series and national database comparison. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 168-172	4.5	0
16	Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?. <i>Practical Radiation Oncology</i> , 2021 , 11, e426-e433	2.8	0
15	Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study. <i>Prostate</i> , 2021 , 81, 1402-1410	4.2	0
14	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021 , 258-259, 61-68	2.3	0
13	Racial Differences in Genomic Profiles of Breast Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e220573	10.4	0
12	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. <i>European Urology Open Science</i> , 2022 , 40, 19-26	0.9	0
11	Editorial Comment. <i>Journal of Urology</i> , 2017 , 197, 348	2.5	
10	Reply to Obesity and aggressive prostate cancer and the golden rule: Do not do to others what you do not want done to yourself. <i>Cancer</i> , 2020 , 126, 2321-2322	6.4	

- 9 Reply to John T. Leppert and James D. Brooks. Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. *Eur Urol* 2018;74:146-54. *European Urology*, **2018**, 74, e112-e113 10.2
- 8 Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 941-948 7.3
- 7 Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines. *Advances in Radiation Oncology*, **2022**, 7, 100832 3.3
- 6 The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. *Journal of Clinical Oncology*, **2014**, 32, 5091-5091 2.2
- 5 Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. *N Engl J Med* 2020;382:2187-96. *European Urology*, **2020**, 78, e195^{10.2}
- 4 Biomarkers in Nonmetastatic Castrate-Resistant Prostate Cancer: A Step in the Right Direction. *JAMA Oncology*, **2021**, 7, 1014-1015 13.4
- 3 Biology vs Access to Care-Relative Contribution to Racial Disparities in Prostate Cancer-In Reply. *JAMA Oncology*, **2019**, 5, 1810-1811 13.4
- 2 Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2019**, 42, 564-572 2.7
- 1 DNA repair and immune checkpoint blockade response.. *Cancer Genetics*, **2022**, 264-265, 1-4 2.3